Moreover, the utilisation of a radiolabelled B1R antagonist for studies using glioma stem cell models and coculture systems with mesenchymal stem cells is required for further advancement of research on stem cell-based therapies for glioblastoma. This evidence concerns the gene BDKRB1 and glioma.